Previous 10 | Next 10 |
2024-03-16 03:43:48 ET Summary Cytokinetics' share price is down 40% from January highs due to Novartis reportedly giving up on acquiring the company, and more recently, due to CEO Blum talking down buyout prospects. Blum said the company had not initiated a sale process and empha...
2024-03-14 18:46:24 ET More on BeiGene BeiGene Still Bleeding Red Ink Despite Blockbuster Drug BeiGene: Debating On Finally Establishing A Position BeiGene gains as access to leukemia drug Brukinsa expands BeiGene gets FDA accelerated approval for Brukinsa fo...
2024-03-14 11:22:56 ET More on Coherus BioSciences Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Q4 2023 Earnings Preview Biggest stock movers today: Boeing, NuSt...
USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Rec...
2024-03-14 08:45:28 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2024 – USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all m...
2024-03-13 18:56:55 ET More on Novartis Novartis And MorphoSys Are A Perfect Match Novartis AG (NVS) Q4 2023 Earnings Call Transcript Novartis AG 2023 Q4 - Results - Earnings Call Presentation Novartis to pay up to $835M for STING antagonist developer IFM Due...
2024-03-13 10:43:27 ET More on Novartis Novartis And MorphoSys Are A Perfect Match Novartis AG (NVS) Q4 2023 Earnings Call Transcript Novartis AG 2023 Q4 - Results - Earnings Call Presentation Radiopharmaceutical market expected to reach ~$14B by 2032 ...
2024-03-12 12:09:42 ET Summary Bicycle Therapeutics plc results from the phase 1/2 Duravelo-1 study, using BT8009 for the treatment of patients with metastatic urothelial carcinoma, expected in the 2nd half of 2024. Data from BT5528 [Bicycle toxin conjugate tech] and BT7480 [Bicyc...
2024-03-11 15:54:09 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q4 2023 Earnings Call Transcript Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade) Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upg...
2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...